Counterpart Health 2025 Results: Enhancing Clinical Decisions to Improve Patient Outcomes and Reduce Costs

Overview of Key 2025 Highlights

Counterpart Health, Inc. (“Counterpart”), a leading AI-powered physician enablement platform and a subsidiary of Clover Health Investments, Corp. (Nasdaq: CLOV), has released significant developments from the year 2025. The platform has consistently showcased its efficacy in chronic disease management, bolstered product expansion, and increased adoption of the Counterpart Assistant (CA) by a substantial number of clinicians across various practice environments.

Clinical Quality and Financial Performance Outcomes

The data for 2025 reveals the extensive impact of Counterpart’s platform on healthcare delivery. The results underscore the cumulative benefits of improved clinical decisions made during patient encounters:

• Clinician Adoption: A remarkable 450% Year-over-Year increase in live third-party customer clinicians, now encompassing hundreds across several states.
• MCR Differential: Clover Health members whose primary care physicians utilize CA displayed an approximate 1,500 basis point differential in Medical Care Ratio (MCR) compared to those who do not.
• Quality Metrics: Counterpart’s technology has achieved the #1 HEDIS score nationwide for a PPO Medicare Advantage plan for the second consecutive year, covering a diverse network of non-employed physicians.

Evidence-Based Clinical Impact

Throughout 2025, Counterpart released multiple retrospective data analyses validating the influence of CA on chronic disease management. The studies highlighted the platform's capability to support proactive care:

• Earlier Disease Identification: New members were 75% more likely to receive a COPD diagnosis within their first year under a CA PCP's care.
• Reductions in Acute Care Utilization: Patients with a CA PCP experienced an 18% lower hospitalization rate for Congestive Heart Failure (CHF) and a 15% lower rate for COPD.
• Support for Disadvantaged Populations: In resource-constrained neighborhoods, CA utilization led to diagnosis rates that were 70-89% higher for key chronic diseases.

Technological Innovation and Enterprise Scaling

Counterpart distinguishes itself by providing actionable insights within the clinical encounter itself, evolving into a comprehensive clinical operating system for value-based care. The platform’s capabilities now extend beyond patient encounters:

• Integrated Ambient Scribing: A solution that captures visit interactions in real time, enabling physicians to concentrate on patient care.
• Natural Language Chat: This feature allows clinicians to inquire about patient histories using natural language, facilitating instant access to information in a secure environment.
• Proactive Visit Summaries: Automated synthesis of data identifies care opportunities prior to patient visits.
• Enterprise-Level Capabilities: Enhanced functionality across quality operations and population health.

Leadership Insights

“When we connect the dots across the healthcare ecosystem, better care moves from a possibility to the norm,” noted Conrad Wai, CEO of Counterpart Health. He emphasized that in 2025, the focus was on fostering better outcomes through improved clinical decisions during patient visits. “Timely, high-fidelity insights enable proactive value-based care to scale effectively,” Wai added.

About Counterpart Health

Counterpart Health, a subsidiary of Clover Health Investments, Corp. (CLOV), is pioneering advancements in physician enablement through data-driven technology. The Counterpart Assistant platform empowers clinicians to deliver high-quality care while enhancing the management of chronic conditions. This technology aims to extend its benefits beyond Clover Health’s Medicare Advantage plan to improve patient outcomes and reduce overall healthcare costs.